CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES THAT RE-DIRECT GLUCOSE METABOLITES OUT OF THE GLYCOLYSIS PATHWAY AND THERAPEUTIC USES THEREOF

Genetically engineered hematopoietic cells, which express one or more factors that redirect glucose metabolites, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide, a chimeric antigen receptor (CAR) polypeptide, or a TCR polypeptide) capable...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MCGINNESS, Kathleen, JENSEN, Amy, BARRON, Luke, BHADURI, Samyabrata, KUIPER, Emily, FRAY, Michael, ETTENBERG, Seth, MOTZ, Gregory, WILSON, Charles
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Genetically engineered hematopoietic cells, which express one or more factors that redirect glucose metabolites, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide, a chimeric antigen receptor (CAR) polypeptide, or a TCR polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.